academic article

• Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  The Journal of rheumatology.  38:1920-4. 2011
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis.  Rheumatology.  2011
• Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  The Journal of Rheumatology.  2011
• Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis..  Rheumatology (Oxford, England).  50:330-4. 2010
• Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument..  Arthritis and rheumatism.  61:1257-63. 2009
• Reliability and Validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2009
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument..  Arthritis and rheumatism.  57:1280-6. 2007
• Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument.  Arthritis & Rheumatism-arthritis Care & Research.  2007
• Development of the scleroderma gastrointestinal tract 1.0 (SSc-GIT1.0) quality of life instrument - Preliminary report.  Arthritis & Rheumatism-arthritis Care & Research.  2006
• Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.  Annals of the Rheumatic Diseases.  2006
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial..  The Journal of rheumatology.  32:832-40. 2005
• Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.  The Journal of Rheumatology.  2005